Poland· PL-100437739
Dentinox N
A medicinal product containing chamomillae tinctura + lidocaini hydrochloridum monohydricum + lauromacrogolum 400, registered in Poland by InPharm Sp. z o.o..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Chamomillae tinctura + Lidocaini hydrochloridum monohydricum + Lauromacrogolum 400
- Manufacturer
- InPharm Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991433048
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b0d869df-91dc-4ee6-ab28-1b94e018d167 GET /v1/drugs/b0d869df-91dc-4ee6-ab28-1b94e018d167?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Żel do stosowania na dziąsła",
"source": "urpl",
"strength": "15 % + 0,34 % + 0,32 %",
"packaging": "05909991433048 ¦ OTC ¦ 136801\n1 tuba 10 g",
"substance": "Chamomillae tinctura 15 % + Lidocaini hydrochloridum monohydricum 0.34 % + Lauromacrogolum 400 0.32 %",
"common_name": "Chamomillae tinctura + Lidocaini hydrochloridum monohydricum + Lauromacrogolum 400",
"pl_product_id": "100437739",
"pozwolenie_nr": "182/20",
"auth_procedure": "IR",
"authorisation_validity": "2030-07-17"
}See everything about chamomillae tinctura + lidocaini hydrochloridum monohydricum + lauromacrogolum 400.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.